Aldeyra Therapeutics (NASDAQ:ALDX) Issues Earnings Results, Misses Expectations By $0.14 EPS

Aldeyra Therapeutics (NASDAQ:ALDX) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.14), Fidelity Earnings reports.

ALDX traded up $0.17 during midday trading on Friday, hitting $5.93. The company’s stock had a trading volume of 163,800 shares, compared to its average volume of 350,763. The firm has a 50-day moving average price of $5.67 and a two-hundred day moving average price of $6.08. Aldeyra Therapeutics has a 52-week low of $4.31 and a 52-week high of $12.79. The firm has a market cap of $167.68 million, a P/E ratio of -3.31 and a beta of 0.84.

A number of research firms recently commented on ALDX. ValuEngine upgraded Aldeyra Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. Cantor Fitzgerald reiterated an “overweight” rating and set a $33.00 price objective on shares of Aldeyra Therapeutics in a research report on Thursday, October 17th. Finally, Zacks Investment Research upgraded Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday. Two research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $24.19.

In other Aldeyra Therapeutics news, CEO Todd C. Brady bought 14,288 shares of the business’s stock in a transaction on Wednesday, September 18th. The shares were bought at an average cost of $5.91 per share, with a total value of $84,442.08. Following the transaction, the chief executive officer now directly owns 614,826 shares in the company, valued at approximately $3,633,621.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Todd C. Brady bought 10,000 shares of the business’s stock in a transaction on Monday, September 9th. The stock was acquired at an average cost of $4.89 per share, for a total transaction of $48,900.00. Following the completion of the transaction, the chief executive officer now owns 50,000 shares in the company, valued at $244,500. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 83,907 shares of company stock worth $456,912. 13.50% of the stock is currently owned by corporate insiders.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency.

Further Reading: Capital Gains Distribution

Earnings History for Aldeyra Therapeutics (NASDAQ:ALDX)

Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.